Pfizer completes acquisition of Icagen
28 October 2011 | By Pfizer
Pfizer Inc. has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen...
List view / Grid view
28 October 2011 | By Pfizer
Pfizer Inc. has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen...
28 October 2011 | By H. Lundbeck A/S
Lundbeck has appointed Jens Peter Balling and Iman Barilero as vice presidents in its research and development organisation...
27 October 2011 | By Mike Claybourn, Raman Product Manager, HORIBA Scientific, 16 rue du Canal, 91160 Longjumeau France
Raman spectroscopy, a technology that has a long pedigree of success in Pharmaceutical Development...
27 October 2011 | By Boehringer Ingelheim
Update across Europe on Pradaxa®...
26 October 2011 | By Biogen Idec
Positive top-line results announced...
26 October 2011 | By Bristol-Myers Squibb Company
Licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination...
26 October 2011 | By GlaxoSmithKline
GSK has joined WIPO Re:Search...
26 October 2011 | By AstraZeneca
US FDA has extended the action date for dapagliflozin for the treatment of type 2 diabetes by three months...
25 October 2011 | By kdm communications
Tecan’s PMP™ option for Freedom EVO® workstations provides Swiss BioQuant with real-time quality control...
24 October 2011 | By H. Lundbeck A/S
The FDA has approved Onfi™ (clobazam)...
24 October 2011 | By Gilead Sciences Inc
Gilead & GlobeImmune enter into an exclusive worldwide license & collaboration agreement...
24 October 2011 | By Abbott
New test based on FISH technology detects chromosomal abnormality to help predict prognosis of patients with AML...
24 October 2011 | By Novartis
Positive results from three Phase II trials...
24 October 2011 | By Sanofi
Sanofi announced the appointment of David Meeker as Chief Executive Officer of Genzyme, effective November 1, 2011...
24 October 2011 | By Merck
Merck announced results from two 26-week investigational Phase III clinical studies...